Answers are grounded in this paper and cite their sources.
The current understanding on the clinical efficacy of Rho-associated protein kinase (ROCK) inhibitor for treating Fuchs endothelial corneal dystrophy is summarized to clarify whether the "off-label" ROCK-inhibitor eye-drop application are appropriate. ROCK-inhibitor eye drops may eventually be deemed a cutting-edge therapy for Fuchs endothelial corneal dystrophy patients with acute corneal endothelial defect.
No takes yet. Share an insight, caveat, or question.
Kinoshita et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: